151 related articles for article (PubMed ID: 18094015)
1. Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
de Visser YP; Walther FJ; Laghmani EH; van Wijngaarden S; Nieuwland K; Wagenaar GT
Eur Respir J; 2008 Mar; 31(3):633-44. PubMed ID: 18094015
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.
de Visser YP; Walther FJ; Laghmani el H; Steendijk P; Middeldorp M; van der Laarse A; Wagenaar GT
Am J Physiol Lung Cell Mol Physiol; 2012 Jan; 302(1):L56-67. PubMed ID: 21949154
[TBL] [Abstract][Full Text] [Related]
3. Inhaled nitric oxide attenuates pulmonary inflammation and fibrin deposition and prolongs survival in neonatal hyperoxic lung injury.
ter Horst SA; Walther FJ; Poorthuis BJ; Hiemstra PS; Wagenaar GT
Am J Physiol Lung Cell Mol Physiol; 2007 Jul; 293(1):L35-44. PubMed ID: 17384081
[TBL] [Abstract][Full Text] [Related]
4. Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats.
Méhats C; Franco-Montoya ML; Boucherat O; Lopez E; Schmitz T; Zana E; Evain-Brion D; Bourbon J; Delacourt C; Jarreau PH
PLoS One; 2008; 3(10):e3445. PubMed ID: 18941502
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
de Visser YP; Walther FJ; Laghmani el H; Boersma H; van der Laarse A; Wagenaar GT
Respir Res; 2009 Apr; 10(1):30. PubMed ID: 19402887
[TBL] [Abstract][Full Text] [Related]
6. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury.
ter Horst SA; Wagenaar GT; de Boer E; van Gastelen MA; Meijers JC; Biemond BJ; Poorthuis BJ; Walther FJ
J Appl Physiol (1985); 2004 Nov; 97(5):2014-9. PubMed ID: 15208286
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.
Wagenaar GT; Sengers RM; Laghmani el H; Chen X; Lindeboom MP; Roks AJ; Folkerts G; Walther FJ
Am J Physiol Lung Cell Mol Physiol; 2014 Aug; 307(3):L261-72. PubMed ID: 24951776
[TBL] [Abstract][Full Text] [Related]
8. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
9. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
10. Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response.
Chen X; Walther FJ; Sengers RM; Laghmani el H; Salam A; Folkerts G; Pera T; Wagenaar GT
Am J Physiol Lung Cell Mol Physiol; 2015 Aug; 309(3):L262-70. PubMed ID: 26047641
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia.
Woyda K; Koebrich S; Reiss I; Rudloff S; Pullamsetti SS; Rühlmann A; Weissmann N; Ghofrani HA; Günther A; Seeger W; Grimminger F; Morty RE; Schermuly RT
Eur Respir J; 2009 Apr; 33(4):861-70. PubMed ID: 19010982
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Cortijo J; Iranzo A; Milara X; Mata M; Cerdá-Nicolás M; Ruiz-Saurí A; Tenor H; Hatzelmann A; Morcillo EJ
Br J Pharmacol; 2009 Feb; 156(3):534-44. PubMed ID: 19154443
[TBL] [Abstract][Full Text] [Related]
14. Deficiency or inhibition of lysophosphatidic acid receptor 1 protects against hyperoxia-induced lung injury in neonatal rats.
Chen X; Walther FJ; van Boxtel R; Laghmani EH; Sengers RM; Folkerts G; DeRuiter MC; Cuppen E; Wagenaar GT
Acta Physiol (Oxf); 2016 Mar; 216(3):358-75. PubMed ID: 26495902
[TBL] [Abstract][Full Text] [Related]
15. Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram.
Johnson FJ; Reynolds LJ; Toward TJ
Toxicol Appl Pharmacol; 2005 Sep; 207(3):257-65. PubMed ID: 16129118
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram.
Chen JC; Chen JQ; Xie QM; Zhu YL
Acta Pharmacol Sin; 2004 Sep; 25(9):1171-5. PubMed ID: 15339393
[TBL] [Abstract][Full Text] [Related]
17. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Spond J; Chapman R; Fine J; Jones H; Kreutner W; Kung TT; Minnicozzi M
Pulm Pharmacol Ther; 2001; 14(2):157-64. PubMed ID: 11273798
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats.
Drummond S; Ramachandran S; Torres E; Huang J; Hehre D; Suguihara C; Young KC
Neonatology; 2015; 107(4):304-11. PubMed ID: 25825119
[TBL] [Abstract][Full Text] [Related]
20. Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis.
Yang D; Yang Y; Zhao Y
Med Sci Monit; 2020 Mar; 26():e922281. PubMed ID: 32231178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
